These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 34888514)
1. Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation. Liang JC; Raman K; Chan SH; Tashakkor AY CJC Open; 2021 Oct; 3(10):1316-1319. PubMed ID: 34888514 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States. Baker CL; Dhamane AD; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Menges B; Lin J; Nadkarni A Adv Ther; 2019 Jan; 36(1):162-174. PubMed ID: 30499067 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting. Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411 [TBL] [Abstract][Full Text] [Related]
5. Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK. Ruigómez A; Vora P; Balabanova Y; Brobert G; Roberts L; Fatoba S; Fernandez O; García Rodríguez LA BMJ Open; 2019 Oct; 9(10):e031342. PubMed ID: 31630107 [TBL] [Abstract][Full Text] [Related]
6. Bullous Pemphigoid-like Skin Eruption during Treatment with Rivaroxaban: A Clinical Case Study. Ferreira C; Oliveira A; Furtado A; Rocha N; Ribeiro JA Eur J Case Rep Intern Med; 2018; 5(3):000724. PubMed ID: 30756013 [TBL] [Abstract][Full Text] [Related]
7. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study. Van Ganse E; Danchin N; Mahé I; Hanon O; Jacoud F; Nolin M; Dalon F; Lefevre C; Cotté FE; Gollety S; Falissard B; Belhassen M; Steg PG Stroke; 2020 Jul; 51(7):2066-2075. PubMed ID: 32539675 [TBL] [Abstract][Full Text] [Related]
8. Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants. Baker CL; Dhamane AD; Rajpura J; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Lin J Clin Appl Thromb Hemost; 2019; 25():1076029619870249. PubMed ID: 31418293 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243 [No Abstract] [Full Text] [Related]
11. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation]. Rudakova AV; Tatarskiĭ BA Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation. Martinez BK; Sood NA; Bunz TJ; Coleman CI J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196 [TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban in atrial fibrillation. Giorgi MA; Miguel LS Vasc Health Risk Manag; 2012; 8():525-31. PubMed ID: 22973107 [TBL] [Abstract][Full Text] [Related]
14. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants. Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883 [No Abstract] [Full Text] [Related]
15. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Harrington AR; Armstrong EP; Nolan PE; Malone DC Stroke; 2013 Jun; 44(6):1676-81. PubMed ID: 23549134 [TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066 [TBL] [Abstract][Full Text] [Related]
17. Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry. Gorczyca I; Jelonek O; Uziębło-Życzkowska B; Chrapek M; Maciorowska M; Wójcik M; Błaszczyk R; Kapłon-Cieślicka A; Gawałko M; Budnik M; Tokarek T; Rajtar-Salwa R; Bil J; Wojewódzki M; Szpotowicz A; Bednarski J; Bakuła-Ostalska E; Tomaszuk-Kazberuk A; Szyszkowska A; Wełnicki M; Mamcarz A; Wożakowska-Kapłon B J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33167503 [TBL] [Abstract][Full Text] [Related]
18. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation. Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551 [TBL] [Abstract][Full Text] [Related]